Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trivalent Dengue Vaccine Efficacy Against DENV-2 Challenge
NCT02433652Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2015
- Primary completion
- Nov 2016
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in dengue fever, sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Adverse Events at 360 days. Started Sep 2015; status: completed.
02
Conditions
dengue fever
Beyond the preview
Go deeper on NCT02433652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02433652.